Amgen Inc. (AMGN) Yield on Cost (YOC): 2.90%
The yield on cost (YOC) for Amgen Inc. (AMGN) is 2.90%.
AMGN Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
2.90%
Yield on Cost for AMGN
AMGN now pays $9.80 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-08) | $158.00 | 6.20% |
| 5 years ago(2021-06-04) | $236.85 | 4.14% |
| 3 years ago(2023-06-06) | $221.22 | 4.43% |
| 1 year ago(2025-06-10) | $293.43 | 3.34% |
| Buying today(at $337.73) | $337.73 | 2.90% |
If you buy today and the dividend keeps growing
Projection: starting from today's 2.90% yield, assuming the dividend keeps compounding at its historical 8.3% rate. Boards set dividends each year, so actual figures will differ.
Today
2.90%
In 3 years
3.92%
In 5 years
4.80%
In 10 years
7.93%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Amgen Inc. (AMGN).
Starting Yield
2.90%
Ending YOC
9.56%
Year 15 Dividend
$32.27
Cum. Dividends Recd.
$294.22
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $9.80 | — | 2.90% | $0.00 |
| Year 1 | $10.61 | +8.27% | 3.14% | $10.61 |
| Year 2 | $11.49 | +8.27% | 3.40% | $22.10 |
| Year 3 | $12.44 | +8.27% | 3.68% | $34.54 |
| Year 4 | $13.47 | +8.27% | 3.99% | $48.00 |
| Year 5 | $14.58 | +8.27% | 4.32% | $62.58 |
| Year 6 | $15.79 | +8.27% | 4.67% | $78.37 |
| Year 7 | $17.09 | +8.27% | 5.06% | $95.46 |
| Year 8 | $18.51 | +8.27% | 5.48% | $113.97 |
| Year 9 | $20.04 | +8.27% | 5.93% | $134.00 |
| Year 10 | $21.69 | +8.27% | 6.42% | $155.69 |
| Year 11 | $23.49 | +8.27% | 6.95% | $179.18 |
| Year 12 | $25.43 | +8.27% | 7.53% | $204.61 |
| Year 13 | $27.53 | +8.27% | 8.15% | $232.14 |
| Year 14 | $29.81 | +8.27% | 8.83% | $261.95 |
| Year 15 | $32.27 | +8.27% | 9.56% | $294.22 |
Amgen Inc. Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Amgen Inc. Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Amgen Inc. (AMGN)?
- The yield on cost (YOC) for AMGN stock is 2.90%.
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Bradway